Latest News for: nsclc

Edit

Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a ...

The Post-Star 22 Apr 2026
Pivotal Phase 3 WU-KONG28 Study of ZEGFROVY® selected as ...
Edit

Synthekine Presents Updated Clinical and Translational Data Demonstrating Strong Activity for STK‑012 in First‑Line Non‑Squamous NSCLC in Oral Presentation at AACR 2026

Pharmiweb 22 Apr 2026
STK-012 + pembrolizumab + chemotherapy in first‑line non‑squamous NSCLC demonstrated a 50% ORR in predominantly PD‑L1-negative patients ... STK11/KEAP1 co‑mutated patients represent approximately 10% of first-line NSQ NSCLC.
Edit

AACR 2026 | HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 22 Apr 2026
HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC ... NSCLC ... About NSCLC.
Edit

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC ...

Nasdaq Globe Newswire 21 Apr 2026
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc ... .
Edit

Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026

PR Newswire 21 Apr 2026
for the treatment of relapsed or refractory NSCLC harboring EGFR exon20ins ... chemo doublet in previously untreated NSCLC patients with EGFR exon20ins mutation ... DZD6008, a 4th Generation EGFR TKI, in Pretreated NSCLC Patients with EGFR C797X Mutations.
Edit

Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting

PR Newswire 21 Apr 2026
Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial ... other than NSCLC in the ARROS-1 study Presenting Author.
Edit

AACR 2026 Poster - TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC) (Genprex Inc)

Public Technologies 20 Apr 2026
‌TROP2 and PTEN are biomarkers of primary resistance to TUSC2 gene therapy in non-small cell lung cancer (NSCLC) ... NSCLC cell lines. Primary resistance to TUSC2 gene therapy in NSCLC PDXOs ... Primary resistance to TUSC2 gene therapy in NSCLC cell lines.
Edit

AACR 2026 | HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 20 Apr 2026
HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS ... nsq-NSCLC without AGAs[1] ... About nsq-NSCLC without AGAs.
Edit

Beamion LUNG-1 study results for zongertinib in treatment-na�ve patients with HER2-mutant advanced NSCLC published in ...

Nasdaq Globe Newswire 16 Apr 2026
This press release is not intended for US or UK media ... .
Edit

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine

PR Newswire 16 Apr 2026
Comprehensive biomarker testing using next generation sequencing determines a patient's eligibility for treatment with HERNEXEOS by identifying HER2 (ERBB2)-mutant advanced NSCLC.1,3 ... advanced NSCLC.
Edit

NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi ...

GetNews 15 Apr 2026
DelveInsight’s report, “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Non-Small Cell Lung Cancer (NSCLC) landscape.
Edit

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 ...

Nasdaq Globe Newswire 13 Apr 2026
The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM.
Edit

NSCLC Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the ...

GetNews 09 Apr 2026
DelveInsight’s "NSCLC Pipeline Insight 2026" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the NSCLC pipeline landscape ... NSCLC Overview ... NSCLC Emerging Drugs Profile V940 ... NSCLC Companies.
Edit

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients (Caris Life Sciences Inc)

Public Technologies 08 Apr 2026
The NSCLC immunotherapy (IO) treatment selection signature was developed to determine which patients benefit from the addition of chemotherapy versus those who are harmed by the addition of chemotherapy.
Edit

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

PR Newswire 08 Apr 2026
The NSCLC immunotherapy (IO) treatment selection signature was developed to determine which patients benefit from the addition of chemotherapy versus those who are harmed by the addition of chemotherapy.

Article Search

tools
×
×
×
×